Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-TUne: Oral Testosterone Undecanoate in Hypogonadal Men
NCT03198728Phase 3Completed
- Sponsor
- Marius Pharmaceuticals
- Start
- Jul 2017
- Primary completion
- May 2020
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of testosterone undecanoate in Hypogonadism (2 arms), sponsored by Marius Pharmaceuticals. Primary endpoint: Percentage of Male Hypogonadal Subjects With Average NaF/EDTA Plasma Total Testosterone (T Cavg) Within the Normal Range at 90 days. Started Jul 2017; status: completed.
02
Drugs
testosterone undecanoate
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT03198728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198728.